Literature DB >> 31770109

CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.

Shi Yong Neo1, Ying Yang1,2, Julien Record3, Ran Ma1, Xinsong Chen1, Ziqing Chen1, Nicholas P Tobin1, Emily Blake4, Christina Seitz5, Ron Thomas4, Arnika Kathleen Wagner6, John Andersson5, Jana de Boniface7,8, Jonas Bergh1, Shannon Murray9, Evren Alici6, Richard Childs10, Martin Johansson11, Lisa S Westerberg4, Felix Haglund1, Johan Hartman1,12, Andreas Lundqvist1.   

Abstract

High levels of ecto-5'-nucleotidase (CD73) have been implicated in immune suppression and tumor progression, and have also been observed in cancer patients who progress on anti-PD-1 immunotherapy. Although regulatory T cells can express CD73 and inhibit T cell responses via the production of adenosine, less is known about CD73 expression in other immune cell populations. We found that tumor-infiltrating NK cells upregulate CD73 expression and the frequency of these CD73-positive NK cells correlated with larger tumor size in breast cancer patients. In addition, the expression of multiple alternative immune checkpoint receptors including LAG-3, VISTA, PD-1, and PD-L1 was significantly higher in CD73-positive NK cells than in CD73-negative NK cells. Mechanistically, NK cells transport CD73 in intracellular vesicles to the cell surface and the extracellular space via actin polymerization-dependent exocytosis upon engagement of 4-1BBL on tumor cells. These CD73-positive NK cells undergo transcriptional reprogramming and upregulate IL-10 production via STAT3 transcriptional activity, suppressing CD4-positive T cell proliferation and IFN-γ production. Taken together, our results support the notion that tumors can hijack NK cells as a means to escape immunity and that CD73 expression defines an inducible population of NK cells with immunoregulatory properties within the tumor microenvironment.

Entities:  

Keywords:  Immunology; NK cells

Mesh:

Substances:

Year:  2020        PMID: 31770109      PMCID: PMC7269592          DOI: 10.1172/JCI128895

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  48 in total

1.  Peripheral 4-1BB signaling negatively regulates NK cell development through IFN-gamma.

Authors:  Beom K Choi; Young H Kim; Chang H Kim; Moon S Kim; Kwang H Kim; Ho S Oh; Myoung J Lee; Don K Lee; Dass S Vinay; Byoung S Kwon
Journal:  J Immunol       Date:  2010-07-07       Impact factor: 5.422

2.  Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases.

Authors:  Dipti Vijayan; Deborah S Barkauskas; Kimberley Stannard; Erin Sult; Rebecca Buonpane; Kazuyoshi Takeda; Michele W L Teng; Kris Sachsenmeier; Carl Hay; Mark J Smyth
Journal:  Oncoimmunology       Date:  2017-04-05       Impact factor: 8.110

Review 3.  Role of mesenchymal stem cells in reestablishing immunologic tolerance in autoimmune rheumatic diseases.

Authors:  Gordon I A MacDonald; Andrea Augello; Cosimo De Bari
Journal:  Arthritis Rheum       Date:  2011-09

Review 4.  Purinergic receptors and nucleotide processing ectoenzymes: Their roles in regulating mesenchymal stem cell functions.

Authors:  Sonia Scarfì
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

5.  A distinct innate lymphoid cell population regulates tumor-associated T cells.

Authors:  Sarah Q Crome; Linh T Nguyen; Sandra Lopez-Verges; S Y Cindy Yang; Bernard Martin; Jennifer Y Yam; Dylan J Johnson; Jessica Nie; Michael Pniak; Pei Hua Yen; Anca Milea; Ramlogan Sowamber; Sarah Rachel Katz; Marcus Q Bernardini; Blaise A Clarke; Patricia A Shaw; Philipp A Lang; Hal K Berman; Trevor J Pugh; Lewis L Lanier; Pamela S Ohashi
Journal:  Nat Med       Date:  2017-02-06       Impact factor: 53.440

6.  Regulatory natural killer cells: new players in the IL-10 anti-inflammatory response.

Authors:  Eric Vivier; Sophie Ugolini
Journal:  Cell Host Microbe       Date:  2009-12-17       Impact factor: 21.023

Review 7.  CD73-adenosine: a next-generation target in immuno-oncology.

Authors:  David Allard; Bertrand Allard; Pierre-Olivier Gaudreau; Pavel Chrobak; John Stagg
Journal:  Immunotherapy       Date:  2016-01-25       Impact factor: 4.196

8.  Improved vectors and genome-wide libraries for CRISPR screening.

Authors:  Neville E Sanjana; Ophir Shalem; Feng Zhang
Journal:  Nat Methods       Date:  2014-08       Impact factor: 28.547

9.  Exosomes in HNSCC plasma as surrogate markers of tumour progression and immune competence.

Authors:  M-N Theodoraki; T K Hoffmann; E K Jackson; T L Whiteside
Journal:  Clin Exp Immunol       Date:  2018-09-19       Impact factor: 4.330

Review 10.  Diverse mechanisms regulate the surface expression of immunotherapeutic target ctla-4.

Authors:  Helga Schneider; Christopher E Rudd
Journal:  Front Immunol       Date:  2014-12-04       Impact factor: 7.561

View more
  57 in total

Review 1.  Regulation of tumor infiltrated innate immune cells by adenosine.

Authors:  Regina Strakhova; Octavia Cadassou; Emeline Cros-Perrial; Lars Petter Jordheim
Journal:  Purinergic Signal       Date:  2020-06-12       Impact factor: 3.765

Review 2.  Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas.

Authors:  Javier Martín-Broto; David S Moura; Brian A Van Tine
Journal:  Clin Cancer Res       Date:  2020-06-29       Impact factor: 12.531

3.  FLT3L Release by Natural Killer Cells Enhances Response to Radioimmunotherapy in Preclinical Models of HNSCC.

Authors:  Thomas E Bickett; Michael Knitz; Laurel B Darragh; Shilpa Bhatia; Benjamin Van Court; Jacob Gadwa; Shiv Bhuvane; Miles Piper; Diemmy Nguyen; Hua Tu; Laurel Lenz; Eric T Clambey; Kevin Barry; Sana D Karam
Journal:  Clin Cancer Res       Date:  2021-09-13       Impact factor: 12.531

4.  Role of NK Cells in Tumor Progression.

Authors:  Iñigo Terrén; Francisco Borrego
Journal:  Exp Suppl       Date:  2022

Review 5.  Interactions between islets and regulatory immune cells in health and type 1 diabetes.

Authors:  Matthew A Budd; Mahdis Monajemi; Sarah J Colpitts; Sarah Q Crome; C Bruce Verchere; Megan K Levings
Journal:  Diabetologia       Date:  2021-09-22       Impact factor: 10.122

6.  Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells.

Authors:  Ying Yang; Shi Yong Neo; Ziqing Chen; Weiyingqi Cui; Yi Chen; Min Guo; Yongfang Wang; Haiyan Xu; Annina Kurzay; Evren Alici; Lars Holmgren; Felix Haglund; Kai Wang; Andreas Lundqvist
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

7.  Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival.

Authors:  Jun Zhao; Luisa M Solis Soto; Hua Wang; Matthew H Katz; Laura R Prakash; Michael Kim; Ching-Wei D Tzeng; Jeffrey E Lee; Robert A Wolff; Yanqing Huang; Ignacio I Wistuba; Anirban Maitra; Huamin Wang
Journal:  Pancreatology       Date:  2021-04-01       Impact factor: 3.996

Review 8.  Targeting CD73 to augment cancer immunotherapy.

Authors:  Meejeon Roh; Derek A Wainwright; Jennifer D Wu; Yong Wan; Bin Zhang
Journal:  Curr Opin Pharmacol       Date:  2020-08-07       Impact factor: 5.547

Review 9.  Optimising NK cell metabolism to increase the efficacy of cancer immunotherapy.

Authors:  Chloe Choi; David K Finlay
Journal:  Stem Cell Res Ther       Date:  2021-06-05       Impact factor: 6.832

10.  Analysis of Autophagy-Related Signatures Identified Two Distinct Subtypes for Evaluating the Tumor Immune Microenvironment and Predicting Prognosis in Ovarian Cancer.

Authors:  Xingyu Chen; Hua Lan; Dong He; Zhanwang Wang; Runshi Xu; Jing Yuan; Mengqing Xiao; Yao Zhang; Lian Gong; Songshu Xiao; Ke Cao
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.